Parnaparin
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Parnaparin: From Anticoagulant Therapy to Breast Fibrocystic Disease
One-Sentence Summary
Parnaparin is a low molecular weight heparin (LMWH) used systemically for anticoagulation and thromboprophylaxis; it is not currently marketed in Taiwan. The TxGNN model’s top-ranked prediction is Breast Fibrocystic Disease, but this direction is supported by no clinical trials and no literature, and the model’s own rationale flags the association as a likely artefact of knowledge-graph proximity rather than a genuine pharmacological link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded for Taiwan (drug unmarketed); internationally used as an LMWH for anticoagulation/thromboprophylaxis |
| Predicted New Indication | Breast Fibrocystic Disease |
| TxGNN Prediction Score | 99.21% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, drug-record-level mechanism-of-action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). However, contextual information captured in the candidate rationale identifies Parnaparin as a low molecular weight heparin (LMWH, ATC B01AB07), which produces anticoagulant effects by activating antithrombin to inhibit Factor Xa (and, to a lesser extent, thrombin/Factor IIa).
For the top-ranked prediction — breast fibrocystic disease, a benign, hormonally-driven proliferative and cystic condition of breast tissue — there is no known or plausible mechanistic pathway connecting Factor Xa inhibition to hormone-sensitive breast tissue pathology. No anti-inflammatory, hormonal, or growth-modulating mechanism links the two. The model’s own repurposing rationale explicitly states that this high TxGNN score likely reflects node proximity within the knowledge graph rather than a validated biological relationship, and notes that the absence of confirmed original-indication data further weakens any mechanistic inference.
By contrast, the second-ranked candidate — thrombophilia due to Protein C deficiency (autosomal recessive) — has a coherent, class-level mechanistic rationale: LMWH agents are an established therapeutic class for thrombosis risk arising from impaired natural anticoagulant pathways. This suggests the underlying model signal for “LMWH ↔ thrombotic disease” is more biologically grounded than the top-ranked breast pathology signal, even though it is still unsupported by drug-specific trial or literature evidence in this dataset.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
No market authorizations are recorded for Parnaparin in Taiwan — the drug has 0 registered licenses and a market status of “Not Marketed.” No approved-indication text is therefore available from Taiwan regulatory sources.
Other Predicted Indications Under Evaluation
This evidence pack (candidate ID TW-DB09260-multi) evaluates three TxGNN-predicted indications for Parnaparin in parallel. For context alongside the primary prediction above:
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 1 | Breast Fibrocystic Disease | 99.21% | L5 | S0 | Hold |
| 2 | Thrombophilia due to Protein C Deficiency (AR) | 99.11% | L4 | S1 | Research Question |
| 3 | Benign Mammary Dysplasia | 99.03% | L5 | S0 | Hold |
Rank 2 carries a stronger class-level mechanistic rationale (LMWH as a recognized option for thrombophilia management) and has progressed further in the internal decision pipeline (S1 vs. S0), despite lacking direct trial or literature support in this dataset. It may be a more productive direction for a formal research question than the top-ranked candidate.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found in the DDI query (result: not found, 0 interactions), and no warnings or contraindications data are currently available for Parnaparin in this evidence pack (DG001, Blocking severity — TFDA label warnings/contraindications not yet retrieved).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Breast Fibrocystic Disease) has evidence level L5 — a model score with no supporting clinical trials or literature — and the drug’s own mechanistic profile (Factor Xa inhibition) has no established pathological link to the predicted condition. In addition, a Blocking-severity data gap (missing TFDA label warnings/contraindications) prevents even a preliminary safety assessment, and Parnaparin has no current market presence in Taiwan.
To proceed, the following is needed:
- TFDA label data (warnings/contraindications) to clear the Blocking gap before any S1 safety review can begin
- Confirmed mechanism-of-action data from DrugBank to validate or refute the mechanistic rationale
- Original approved-indication data for Parnaparin to establish a proper baseline for similarity assessment
- If pursuing further work, prioritize the Protein C deficiency thrombophilia candidate (rank 2) over breast fibrocystic disease, given its stronger class-level mechanistic plausibility and more advanced decision-stage status (S1, Research Question)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.